These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33527208)

  • 1. Teicoplanin physiologically based pharmacokinetic modeling offers a quantitative assessment of a theoretical influence of serum albumin and renal function on its disposition.
    Emoto C; Johnson TN; Yamada T; Yamazaki H; Fukuda T
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1157-1168. PubMed ID: 33527208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection.
    Ogawa R; Kobayashi S; Sasaki Y; Makimura M; Echizen H
    Int J Clin Pharmacol Ther; 2013 May; 51(5):357-66. PubMed ID: 23458228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
    Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
    J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically Based Pharmacokinetic Modeling and Dose Adjustment of Teicoplanin in Pediatric Patients With Renal Impairment.
    Xu J; Lin R; Chen Y; You X; Huang P; Lin C
    J Clin Pharmacol; 2022 May; 62(5):620-630. PubMed ID: 34761398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftaroline Dosage Optimized for Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling.
    Zhou J; You X; Guo G; Ke M; Xu J; Ye L; Wu W; Huang P; Lin C
    J Clin Pharmacol; 2021 Dec; 61(12):1646-1656. PubMed ID: 34329494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential.
    Willmann S; Coboeken K; Kapsa S; Thelen K; Mundhenke M; Fischer K; Hügl B; Mück W
    J Clin Pharmacol; 2021 May; 61(5):656-665. PubMed ID: 33205449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A GFR-Based Method to Predict the Effect of Renal Impairment on the Exposure or Clearance of Renally Excreted Drugs: A Comparative Study Between a Simple GFR Method and a Physiologically Based Pharmacokinetic Model.
    Mahmood I
    Drugs R D; 2020 Dec; 20(4):377-387. PubMed ID: 33150526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.
    Li GF; Wang K; Chen R; Zhao HR; Yang J; Zheng QS
    Acta Pharmacol Sin; 2012 Nov; 33(11):1359-71. PubMed ID: 23085739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics and Pharmacodynamics of Teicoplanin and C-Reactive Protein in Hospitalized Patients With Gram-Positive Infections.
    Ogami C; Tsuji Y; Muraki Y; Mizoguchi A; Okuda M; To H
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):175-188. PubMed ID: 30934169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using a Vancomycin PBPK Model in Special Populations to Elucidate Case-Based Clinical PK Observations.
    Emoto C; Johnson TN; McPhail BT; Vinks AA; Fukuda T
    CPT Pharmacometrics Syst Pharmacol; 2018 Apr; 7(4):237-250. PubMed ID: 29446256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment.
    Wu W; Ke M; Ye L; Lin C
    Eur J Clin Pharmacol; 2021 Jul; 77(7):989-998. PubMed ID: 33447912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Theoretical Physiologically-Based Pharmacokinetic Approach to Ascertain Covariates Explaining the Large Interpatient Variability in Tacrolimus Disposition.
    Emoto C; Johnson TN; Hahn D; Christians U; Alloway RR; Vinks AA; Fukuda T
    CPT Pharmacometrics Syst Pharmacol; 2019 May; 8(5):273-284. PubMed ID: 30843669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
    Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
    Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal Teicoplanin Dosing Regimen in Neonates and Children Developed by Leveraging Real-World Clinical Information.
    Yamada T; Emoto C; Fukuda T; Motomura Y; Inoue H; Ohga S; Ieiri I
    Ther Drug Monit; 2022 Jun; 44(3):404-413. PubMed ID: 34629445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy.
    Byrne CJ; Roberts JA; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; Ryder SA; D'Arcy DM; McHugh J
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non-complicated methicillin-resistant staphylococcus aureus infection.
    Zhang XS; Chen YL; Wang YZ; Chen C; Chen YJ; Xu FM; Dai Y; Shi DW; Lin GY; Yu XB; Xiang DZ; Zhang CH
    Br J Clin Pharmacol; 2024 Feb; 90(2):452-462. PubMed ID: 37749762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Physiologically Based Pharmacokinetic Model for Prediction of Pramipexole Pharmacokinetics in Parkinson's Disease Patients With Renal Impairment.
    You X; Wu W; Xu J; Jiao Z; Ke M; Huang P; Lin C
    J Clin Pharmacol; 2020 Aug; 60(8):999-1010. PubMed ID: 32090332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.
    Cazaubon Y; Venisse N; Mimoz O; Maire P; Ducher M; Bourguignon L; Goutelle S
    J Antimicrob Chemother; 2017 Oct; 72(10):2804-2812. PubMed ID: 29091222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation.
    Yamada T; Nonaka T; Yano T; Kubota T; Egashira N; Kawashiri T; Oishi R
    Int J Antimicrob Agents; 2012 Oct; 40(4):344-8. PubMed ID: 22818770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of teicoplanin.
    Rowland M
    Clin Pharmacokinet; 1990 Mar; 18(3):184-209. PubMed ID: 2138946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.